Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study

View Full Paper
Ask AI
Bookmark
Share

Authors

CFCécile FavreauGVGeoffroy VentonMLMichaël Loschi

Discussion

Loading...

Member takes

Overview

Pilot study demonstrates treatment response prediction in AML using venetoclax, azacitidine, and BH3 profiling.

Key Points

  • To examine predictive factors for treatment response to azacitidine and venetoclax in AML patients.
  • Prospective collection of blood samples from AML patients treated with AZA + VEN.
  • BH3 profiling and phospho-flow cytometry conducted to assess Bcl-2 inhibition.
  • Responses evaluated according to ELN 2022 criteria.
  • The CRc rate after two cycles of AZA + VEN was 35%.
  • Inter-individual variability in venetoclax plasma levels was observed with a median of 1239 ng/mL.
  • BH3 profiling predicted venetoclax resistance early in treatment.

Cite This Study

Favreau et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e044https://doi.org/10.1182/blood-2025-5250
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5184: Biomarker results from PEVENAZA, a randomized phase 2 study of venetoclax and azacitidine +/- pevonedistat in newly diagnosed AML patients unfit for intensive chemotherapy: Increased efficacy in a subset of patients with IDH1/2 mutations and other observations2024
  2. 2Abstract 5852: Tumor gene expression patterns affecting response to BCl-2 inhibitor venetoclax in acute myeloid leukemia2024
  3. 3Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia2026 · 1 citations
  4. 4Abstract 2439: Predictive modeling of venetoclax/azacitidine response in acute myeloid leukemia using inflammatory cytokine profiling and clinical data from the NCT04267081 trial cohort2026
  5. 5Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study2024